These findings revealed the significance of the lncRNA DLGAP1‐AS2/miR‐505/GALNT10 axis in the malignant progression of CCA and supply a novel target for the CCA diagnosis and therapy. This evidence concerns the gene GALNT10 and cholangiocarcinoma.